Alector Stock News

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the companys immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

Company''s deal with Oxford University follows July pact with Alector Check out Paul Singer Stock Picks » Download GuruFolio Report of Paul Singer (Updated on 12/05/2021) Related Stocks: GSK , ALEC , PPH , PFE , LLY , AZN , BMY , ME ,

Shares of Alector, Inc. (NASDAQ:ALEC) traded up 4.3% during trading on Tuesday . The company traded as high as $20.47 and last traded at $20.19. 11,921 shares were traded during mid-day trading, a decline of 98% from the average session volume of 493,971 shares. The stock had previously closed at $19.35. A number of analysts […]

Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET

Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Eliza

There has been a major shakeup in the C-suite.

Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer

Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontot

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET